Does Rallies show Form 4 insider transactions for ATRC?

Yes. Rallies tracks ATRC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ATRC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATRC. It does not provide personalized investment advice.

ATRC (AtriCure, Inc.) Stock Analysis - Insider Trades

AtriCure, Inc. (ATRC) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRC trades at $29.00 with a market cap of $1.44B and a P/E ratio of -288.90. ATRC moved +0.69% today. Year to date, ATRC is -28.43%; over the trailing twelve months it is -14.83%. Its 52-week range spans $25.52 to $43.18. Analyst consensus is strong buy with an average price target of $50.29. Rallies surfaces ATRC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ATRC stock inside the company?

Recent ATRC insider activity includes Doraiswamy Vinayak sold 5.00K, Noznesky Justin J sold 5.17K, WEHRWEIN SVEN sold 4.97K, WEHRWEIN SVEN sold 5.03K, and Yuen Maggie sold 3.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ATRC Key Metrics

Key financial metrics for ATRC
Metric	Value
Price	$29.00
Market Cap	$1.44B
P/E Ratio	-288.90
EPS	$-0.10
Dividend Yield	0.00%
52-Week High	$43.18
52-Week Low	$25.52
Volume	518.30K
Avg Volume	0
Revenue (TTM)	$552.16M
Net Income	$-4.59M
Gross Margin	75.61%

Recent ATRC Insider Trades

Doraiswamy Vinayak sold 5.00K (~$149.15K) on Mar 12, 2026.
Noznesky Justin J sold 5.17K (~$192.64K) on Nov 26, 2025.
WEHRWEIN SVEN sold 4.97K (~$188.75K) on Nov 25, 2025.
WEHRWEIN SVEN sold 5.03K (~$187.83K) on Nov 24, 2025.
Yuen Maggie sold 3.00K (~$107.16K) on Nov 21, 2025.

Latest ATRC News

AtriCure Tops Q3 Revenue Estimates, Forecasts 109% FY2026 Earnings Growth — Feb 18, 2026
AtriCure Raises 2026 Revenue Guidance to $600–$610M After 13% Q4 Growth — Feb 18, 2026
AtriCure Q3 Loss Narrows 90.9%, Revenue Beats by 2.1% — Feb 17, 2026
Stryker Launches T2 Alpha Humerus Nail with 6 mm Compression — Feb 12, 2026
AtriCure Q3 Loss Narrows to $0.01; Revenue Tops $134M, 92% Growth Forecast — Feb 9, 2026

ATRC Analyst Consensus

8 analysts cover ATRC: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.29.

Common questions about ATRC

Who is trading ATRC stock inside the company?: Recent ATRC insider activity includes Doraiswamy Vinayak sold 5.00K, Noznesky Justin J sold 5.17K, WEHRWEIN SVEN sold 4.97K, WEHRWEIN SVEN sold 5.03K, and Yuen Maggie sold 3.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ATRC?: Yes. Rallies tracks ATRC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ATRC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATRC. It does not provide personalized investment advice.